Catherine Nguyen
 
                    Education
M.P.H, epidemiology and biostatistics, UCLA Fielding School of Public Health; B.S., human biology and society, University of California, Los Angeles
Summary of Experience
Ms. Nguyen specializes in epidemiology, treatment effectiveness, and health outcomes research. She has experience with observational and regulatory studies, including FDA post-authorization safety studies. Ms. Nguyen has used insurance claims, medical chart review, electronic medical records, and other health care data across a range of disease areas, including cancer, cystic fibrosis, COVID-19, depression, and asthma. She has conducted studies to answer research questions related to treatment patterns, comparative effectiveness, drug safety, and health care resource utilization and cost. Prior to joining Analysis Group, Ms. Nguyen worked at the local, state, and federal levels of government, which included assessing community hypertension prevention programs and investigating tuberculosis outbreaks in California. She has presented research at conferences with a variety of stakeholders and published manuscripts in a number of peer-reviewed journals.
- 
                                                        Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosisThorax, 2024 
 2024Merlo CA, McGarry LJ, Thorat T, Nguyen C, DerSarkissian M, Muthukumar A, Healy J, Brookhart MA, Rubin JL 
- 
                                                        Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosisThorax, 2024 
 2024Merlo CA, Thorat T, DerSarkissian M, McGarry LJ, Nguyen C, Gu YM, Healy J, Rubin JL, Brookhart MA 
- 
                                                        Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximabCurrent Medical Research and Opinion, 2022 
 2022Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y 
- 
                                                        The acute effects of azithromycin use on cardiovascular mortality as compared with amoxicillin-clavulanate in US VeteransPharmacoepidemiology and Drug Safety, 2022 
 2022DerSarkissian M, Young-Xu Y, Duh MS, Bhak RH, Palmetto N, Mortensen E, Anzueto A, Nguyen C, Cheng M, Frajzyngier V, Park S, Lax A, Weatherby LB, Walker AM 
- 
                                                        Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal IrinotecanFrontiers in Oncology, 2021 
 2021Yu KH, Hendifar AE, Alese OB, Draper A, Abdelrahim M, Burns E, Khan G, Cockrum P, Bhak RH, Nguyen C, DerSarkissian M, Duh MS, Bahary N 
- 
                                                        Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseInternational Journal of Chronic Obstructive Pulmonary Disease, 2021 
 2021Mapel DW, Roberts MH, Sama S, Bobbili PJ, Cheng WY, Duh MS, Nguyen C, Thompson-Leduc P, Van Dyke MK, Rothnie KJ, Sundaresan D, Certa JM, Whiting TS, Brown JL, Roblin DW 
- 
                                                        Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell CarcinomaClinical Genitourinary Cancer, 2019 
 2019Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC 
- 
                                                        August 24, 2024
- 
                                                    August 26, 2024
- 
                                                    August 30, 2022
